Table 1.

Antimalarial formulation based on passive drug targeting mechanism

S. no.	Drug	Formulation	Comments	Reference
1.	Artemisinin	PEGylated liposome	AUC values enhanced; half-life of the drug-enhanced by greater than 5 times.	[14]
2.	Trans platinum–chloroquine diphosphate dichloride (PtCQ)	PEGylated neutral and cationic liposomes	Encapsulation efficiency 76.1 ± 6.7% for neutral liposomes, 70.4 ± 9.8% for cationic liposomes, good stability	[15]
3.	Artesunate	PEGylated	PEGylated artesunate enhanced water solubility and circulation half-life in vivo with better activity.	[16]
4.	Dihydroartemisinin (DHA)	PEGylated lipid nanoemulsion	Nanoemulsion exhibits no hemolysis of the RBCs and exhibited rapid parasite clearance.	[17]
5.	Monensin	PEGylated liposome	Formulation shows higher efficacy as compared wih the free monensin in the Plasmodium falciparum 3D7 culture and mice model of P. berghei strains NK65 and ANKA exhibited better antiparasitic activity. Circulation half-life and in combination with free artemisinin exhibited greater parasite clearance, inhibited reoccurrence	[18]
6.	Artesunate	Nanocapsule	Artesunate-heparin conjugated nanocapsules (ART-HEP-NCPs) inhibited in vitro P. falciparum 3D7 and an extended circulation in blood.	[19]